CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8+ T cell frequency and patient survival

Human Immunology

Volumn 75, Issue 7, 2014, Pages 614-620

  Weiss, Jonathan M ^a   Gregory Alvord, W ^b   Quiñones, Octavio A ^b   Stauffer, Jimmy K ^a   Wiltrout, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Apoptosis; CD40; CD8; Renal cell carcinoma; Survival

Indexed keywords

CD40 ANTIGEN; CD8 ANTIGEN; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; UPREGULATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETICS; KIDNEY; KIDNEY TUMOR; LYMPHOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ANTIGENS, CD40; APOPTOSIS; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IN SITU NICK-END LABELING; KIDNEY; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84902254477     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.04.018     Document Type: Article

References (47)

1. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135.
2. van Kooten C., Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000, 67(1):2-17.
3. Schulz O., Edwards A.D., Schito M., Aliberti J., Manickasingham S., Sher A., et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000, 13(4):453-462.
4. Eliopoulos A.G., Davies C., Knox P.G., Gallagher N.J., Afford S.C., Adams D.H., et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000, 20(15):5503-5515.
5. Laxmanan S., Datta D., Geehan C., Briscoe D.M., Pal S. CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol 2005, 16(9):2714-2723.
6. Li H., Nord E.P. CD40 ligation stimulates MCP-1 and IL-8 production, TRAF6 recruitment, and MAPK activation in proximal tubule cells. Am J Physiol Renal Physiol 2002, 282(6):F1020-F1033.
7. Li H., Nord E.P. CD40/CD154 ligation induces mononuclear cell adhesion to human renal proximal tubule cells via increased ICAM-1 expression. Am J Physiol Renal Physiol 2005, 289(1):F145-F153.
8. Yellin M.J., D'Agati V., Parkinson G., Han A.S., Szema A., Baum D., et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997, 40(1):124-134.
9. Kluth B., Hess S., Engelmann H., Schafnitzel S., Riethmuller G., Feucht H.E. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res 1997, 57(5):891-899.
10. Bussolati B., Russo S., Deambrosis I., Cantaluppi V., Volpe A., Ferrando U., et al. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int J Cancer 2002, 100(6):654-661.
11. Lee J.K., Seki N., Sayers T.J., Subleski J., Gruys E.M., Murphy W.J., et al. Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol 2005, 235(2):145-152.
12. Shorts L., Weiss J.M., Lee J.K., Welniak L.A., Subleski J., Back T., et al. Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol 2006, 176(11):6543-6552.
13. van den Oord J.J., Maes A., Stas M., Nuyts J., Battocchio S., Kasran A., et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 1996, 149(6):1953-1961.
14. Li R., Chen W.C., Pang X.Q., Hua C., Li L., Zhang X.G. Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. Int J Mol Sci 2009, 10(9):3900-3917.
15. Ishikawa K., Miyamoto M., Yoshioka T., Kato T., Kaji M., Ohbuchi T., et al. Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis. Cancer 2008, 113(3):530-541.
16. Kinouchi M., Miura K., Mizoi T., Ishida K., Fujibuchi W., Sasaki H., et al. Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. Hepatogastroenterology 2012, 60(121).
17. Sathawane D., Kharat R.S., Halder S., Roy S., Swami R., Patel R., et al. Monocyte CD40 expression in head and neck squamous cell carcinoma (HNSCC). Hum Immunol 2013, 74(1):1-5.
18. Slobodova Z., Ehrmann J., Krejci V., Zapletalova J., Melichar B. Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. Neoplasma 2011, 58(3):189-197.
19. Wingett D.G., Vestal R.E., Forcier K., Hadjokas N., Nielson C.P. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998, 50(1):27-36.
20. Zhou Y., He J., Gou L.T., Mu B., Liao W.C., Ma C., et al. Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells. Cancer Immunol Immunother 2012, 61(10):1735-1743.
21. Wu Y., Wang L., He X., Xu H., Zhou L., Zhao F., et al. Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo. Cell Immunol 2008, 253(1-2):102-109.
22. Vonderheide R.H. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007, 13(4):1083-1088.
23. Vonderheide R.H., Glennie M.J. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013, 19(5):1035-1043.
24. Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., et al. Cell profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006, 7(10):R100.
25. Team RC (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing. http://www.R-project.org/.
26. Shugart J.A., Bambina S., Alice A.F., Montler R., Bahjat K.S. A self-help program for memory CD8+ T cells: positive feedback via CD40-CD40L signaling as a critical determinant of secondary expansion. PLoS ONE 2013, 8(5):e64878.
27. Genega E.M., Ghebremichael M., Najarian R., Fu Y., Wang Y., Argani P., et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 2010, 134(6):873-879.
28. Gallagher N.J., Eliopoulos A.G., Agathangelo A., Oates J., Crocker J., Young L.S. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol 2002, 55(2):110-120.
29. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008, 222:357-368.
30. Thompson J.A., Figlin R.A., Sifri-Steele C., Berenson R.J., Frohlich M.W. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 2003, 9(10 Pt. 1):3562-3570.
31. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987, 316(15):889-897.
32. Belldegrun A., Muul L.M., Rosenberg S.A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988, 48(1):206-214.
33. Arima K., Nakagawa M., Yanagawa M., Sugimura Y., Tochigi H., Kawamura J. Prognostic factors of peripheral blood lymphocyte subsets in patients with renal cell carcinoma. Urol Int 1996, 57(1):5-10.
34. Tomita Y., Nishiyama T., Fujiwara M., Sato S. Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. Br J Cancer 1990, 62(3):354-359.
35. Kondo T., Ito F., Nakazawa H., Horita S., Osaka Y., Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004, 171(6 Pt. 1):2171-2175.
36. Gohring B., Riemann D., Rebmann U., Heynemann H., Schabel J., Langner J. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Urol Res 1996, 24(5):297-303.
37. Characiejus D., Pasukoniene V., Kazlauskaite N., Valuckas K.P., Petraitis T., Mauricas M., et al. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 2002, 22(6B):3679-3683.
38. Hernberg M., Muhonen T., Pyrhonen S. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?. Ann Oncol 1997, 8(1):71-77.
39. Lei Y., Geng Z., Guo-Jun W., He W., Jian-Lin Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem 2010, 344(1-2):23-31.
40. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17(25):3247-3259.
41. Yuan Q.Z., Wang C.T., Mao Y.Q., Zhang P., Shi H.S., Li Z.Y., et al. Enhanced tumor radiosensitivity by a survivin dominant-negative mutant. Oncol Rep 2010, 23(1):97-103.
42. Virrey J.J., Guan S., Li W., Schonthal A.H., Chen T.C., Hofman F.M. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008, 173(2):575-585.
43. Muriel Lopez C., Esteban E., Astudillo A., Pardo P., Berros J.P., Izquierdo M., et al. Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs 2012, 30(6):2443-2449.
44. Stillebroer A.B., Mulders P.F., Boerman O.C., Oyen W.J., Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010, 58(1):75-83.
45. Zhou G.X., Ireland J., Rayman P., Finke J., Zhou M. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology 2010, 75(2):257-261.
46. Zhang B.Y., Thompson R.H., Lohse C.M., Dronca R.S., Cheville J.C., Kwon E.D., et al. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int 2013, 111(7):1046-1053.
47. Buhtoiarov I.N., Lum H.D., Berke G., Sondel P.M., Rakhmilevich A.L. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 2006, 176(1):309-318.